查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2005109

次世代定序(NGS) CLIA 检测服务市场：按服务类型、应用、最终用户、技术平台和检体类型划分－2026-2032 年全球市场预测

Next Generation Sequencing CLIA Laboratory Services Market by Service Type, Application, End User, Technology Platform, Sample Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，次世代定序(NGS) CLIA 侦测服务市值将达到 77.1 亿美元，到 2026 年将成长至 88.1 亿美元，到 2032 年将达到 192.1 亿美元，复合年增长率为 13.92%。

主要市场统计数据
基准年 2025 77.1亿美元
预计年份：2026年 88.1亿美元
预测年份 2032 192.1亿美元
复合年增长率 (%) 13.92%

对重组 CLIA 认证的次世代定序检查室服务的营运现实和策略挑战进行了引人入胜的概述。

临床分子诊断领域正迅速走向成熟，次世代定序(NGS)调查方法日益融入常规临床工作流程。本执行摘要全面而实用地观点了 CLIA 认证的 NGS 检测服务的发展现状、重塑服务交付的技术和营运转折点，以及领导者为保持竞争力应考虑的战略选择。摘要还阐述了临床EXOME、标靶基因panel和全基因组策略在不断变化的支付方期望、日益严格的监管以及对精准医疗日益增长的需求等因素共同作用下的商业环境。

展望未来，概述技术、监管和营运方面的变化，这些变化将重新定义次世代定序服务的交付和伙伴关係。

由于多种因素的共同作用，基于次世代定序的CLIA认证检查室服务格局正在经历一场变革。儘管技术进步降低了高通量定序的进入门槛，但分析的复杂性却日益增加，迫使检查室迅速改善检测设计、检验框架和资讯处理流程。新的定序平台和化学技术的改进正在改变人们对通量经济性和数据品质的考量，进而影响着标靶基因组定序、EXOME序和全基因组检测等临床检测方法的选择。

对近期关税调整如何重塑临床 NGS检查室的采购韧性、营运连续性和供应商策略进行严格分析。

美国将于2025年实施新的关税措施，将对依赖全球供应链的CLIA认证的次世代定序检查室产生即时且连锁的影响。进口试剂、耗材和仪器组件的关税将增加单位成本，并使长期采购计画更加复杂。先前基于可预测的供应商价格优化成本结构的检查室，现在需要评估其成本基础对关税波动的敏感性，并考虑避险策略、多供应商采购或近岸外包等措施来降低风险。

对决定操作和解释复杂性的服务类型、临床应用、最终用户、平台技术和检体相关因素进行详细分析。

深入的细分揭示了临床价值与操作复杂性在服务类型、应用、最终用户、技术平台和检体类型之间的交集。服务类型（临床EXOME序、标靶基因panel检测和全基因组定序）的差异体现在检验负担和临床报告要求的不同。临床EXOME定序方法分为成人和儿童EXOME，需要专门的解读流程以及不同的知情同意和变异註释实践。同时，针对癌症、心血管疾病和神经系统疾病的标靶基因panel检测为特定的临床效用提供了可扩展的方法。在癌症panel检测中，血液系统恶性肿瘤panel和固态肿瘤panel之间的区别导致了不同的检体处理要求和生物资讯工作流程，检查室必须仔细考虑这些差异。

对全球主要地区临床基因组学服务的监管细微差别、检体获取趋势和获取途径进行区域分析。

地理因素持续影响美洲、欧洲、中东、非洲和亚太地区定序平台的取得、试剂供应链、监管解读以及临床应用率，导致各地区检查室的策略重点有所不同。在美洲，综合医疗保健系统和先进的肿瘤中心正在推动对伴随诊断和高复杂度定序服务的需求，而法规环境强调CLIA认证和与保险公司的合作，以实现临床认可和规模化应用。

对决定临床定序服务竞争优势的供应商定位、整合解决方案策略和伙伴关係模式进行详细分析。

主要企业之间的竞争格局取决于其技术组合的广度、全球製造和供应链的稳健性、试剂和耗材生态系统，以及生物资讯学和临床报告支援的全面性。领先的定序平台供应商不仅在先导化合物的准确性和通量上竞争，还在下游服务（例如检测试剂盒、参考资料资料库和整合资讯学解决方案）方面竞争，这些服务能够降低临床检验的时间和成本。平台供应商与诊断检查室之间的策略伙伴关係，透过协调检验流程和供应保障，加速了检测部署；而投资于试剂可靠性和​​本地化生产的公司，则在供应紧张的情况下获得了营运优势。

检查室经营团队的可操作策略重点，重点在于采购弹性、临床差异化和可扩展的卓越营运。

产业领导者必须采取双管齐下的策略，在短期营运韧性和长期临床差异化之间取得平衡。首先，优先考虑供应商多元化和长期合约结构，以抵御供应链波动和关税影响。这包括评估替代供应商、建立本地生产伙伴关係以及製定库存策略，以确保临床服务的连续性。其次，投资于模组化自动化和标准化品质体系，以加快检测检验、降低错误率并支援可扩展的吞吐量，同时确保临床解读的严谨性。

透明的调查方法，结合与关键相关人员的访谈、技术检验审查和基于场景的压力测试，为营运实施提供可操作的见解。

本研究整合了与关键相关人员（包括检查室管理人员、平台供应商、临床相关人员和专家）的对话，并系统地回顾了监管指南、同行评审文献和供应商技术文檔，从而得出全面而实用的评估。调查方法强调三角验证：定性访谈反映实际操作情况，技术检验和通讯协定审查揭示检测性能的局限性，平台规格的比较分析则确定与临床实施相关的权衡取舍。

一项旨在促进临床基因组学服务永续发展的策略执行、供应商韧性和临床证据途径的全面整合。

总而言之，CLIA认证的次世代定序检查室服务正处于一个转折点，技术进步、供应链趋势、监管预期和不断演变的临床应用模式在此交汇，既带来了挑战，也带来了机会。积极提升采购韧性、投资建构强大的生物资讯学解读框架、并与平台供应商和临床相关人员建立伙伴关係的检查室，将更有能力将技术能力转化为可靠且具有临床实用性的服务。标靶基因组定序、EXOME序和全基因组检测的相互作用，需要从组合角度出发，使检测选择与临床效用、营运能力和监管要求一致。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章次世代定序(NGS) CLIA 侦测服务市场：依服务类型划分

  • 临床EXOME定序
    • 成人EXOME
    • 儿童EXOME
  • 标靶基因检测
    • 癌症小组
      • 血液疾病检测
      • 固态肿瘤组
    • 心血管小组
    • 神经系统疾病组
  • 全基因组定序

第九章次世代定序(NGS) CLIA 侦测服务市场：依应用领域划分

  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 遗传性疾病
    • 一般疾病
    • 罕见疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固态肿瘤
  • 药物基因体学
  • 生殖医学
    • 非侵入性产前检测
    • 胚胎着床前遗传学检测

第十章次世代定序(NGS) CLIA 侦测服务市场：依最终使用者划分

  • 诊断检测实验室
  • 消费者测试
  • 医院和诊所
  • 研究机构

第十一章 按技术平台分類的次世代定序(NGS) CLIA 检测服务市场

  • 华大基定序平台
    • BGI-Seq 500
    • Mgiseq
  • Illumina定序平台
    • MiSeq
    • NextSeq
    • NovaSeq
  • Thermo Fisher定序平台
    • Ion Torrent PGM
    • Ion Torrent Proton

第十二章次世代定序(NGS) CLIA 检测服务市场（检体类型划分）

  • 血
    • 电浆
    • 全血
  • 唾液
  • 组织
    • FFPE
    • 新鲜冷冻

第十三章次世代定序(NGS) CLIA 侦测服务市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章次世代定序(NGS) CLIA 侦测服务市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章次世代定序(NGS) CLIA 检测服务市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国次世代定序(NGS) CLIA 侦测服务市场

第十七章：中国次世代定序（NGS）CLIA检测服务市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies Inc
  • ARUP Laboratories
  • Azenta Life Sciences
  • BGI Genomics Co Ltd
  • Bio-Rad Laboratories Inc
  • Charles River Laboratories Inc
  • Eurofins Scientific SE
  • F Hoffmann-La Roche AG
  • Foundation Medicine Inc
  • Fulgent Genetics Inc
  • Guardant Health Inc
  • Illumina Inc
  • Invitae Corporation
  • IQVIA Laboratories
  • Macrogen Inc
  • Myriad Genetics Inc
  • Natera Inc
  • NeoGenomics Laboratories
  • Novogene Corporation
  • Oxford Nanopore Technologies plc
  • Personalis Inc
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc
  • Veracyte Inc
Product Code: MRR-C41945B3D381

The Next Generation Sequencing CLIA Laboratory Services Market was valued at USD 7.71 billion in 2025 and is projected to grow to USD 8.81 billion in 2026, with a CAGR of 13.92%, reaching USD 19.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.71 billion
Estimated Year [2026] USD 8.81 billion
Forecast Year [2032] USD 19.21 billion
CAGR (%) 13.92%

A compelling introduction to the operational realities and strategic imperatives reshaping CLIA-certified next generation sequencing laboratory services

The clinical molecular diagnostics landscape is entering a phase of accelerated maturation where next generation sequencing (NGS) methodologies are increasingly embedded in routine clinical workflows. This executive summary introduces a comprehensive and pragmatic view of how CLIA-certified NGS laboratory services are evolving, the technology and operational inflection points reshaping service delivery, and the strategic choices leaders must deliberate to remain competitive. It frames the business context in which clinical exome, targeted gene panels, and whole genome strategies coexist alongside shifting payer expectations, tighter regulatory scrutiny, and rising demand for precision therapeutics.

Transitioning from development to clinical scale requires an integrated perspective that spans technology platform selection, sample logistics, bioinformatics pipelines, and quality management systems. The Introductory section therefore situates readers within the operational realities of accredited laboratories, highlighting how end users-from hospitals to direct-to-consumer channels-are changing requisition patterns and expectations for turnaround, interpretive clarity, and clinical utility. By focusing on pragmatic change drivers rather than abstract projections, this section prepares decision-makers to interpret subsequent insights and to prioritize investments that yield measurable clinical and commercial returns.

A forward-looking synthesis of technological, regulatory, and operational shifts redefining clinical next generation sequencing service delivery and partnerships

The landscape for CLIA laboratory services powered by next generation sequencing is undergoing transformative shifts driven by several converging forces. Technological progress is lowering the barrier to high-throughput sequencing while simultaneously increasing analytical complexity, compelling laboratories to iterate rapidly on assay design, validation frameworks, and informatics pipelines. Newer sequencing platforms and chemistry refinements are changing throughput economics and data quality considerations, which in turn affect clinical assay choices between targeted panels, exome approaches, and whole genome testing.

Alongside technology, regulatory and reimbursement environments are evolving. Laboratories are adapting to more stringent validation expectations, transparency around variant interpretation, and the need for robust clinical evidence to support diagnostic claims. Payer policies are increasingly focused on demonstrable clinical utility and value-based outcomes, prompting laboratories to emphasize assay standardization, clinical reporting consistency, and longitudinal data collection. Concurrently, the rise of precision oncology and the integration of genomic data into electronic health records are driving tighter collaboration between diagnostic providers, hospitals, and therapeutics developers, creating new service models such as companion diagnostics and longitudinal genomic surveillance.

Operationally, workforce constraints and the need for specialized bioinformatics expertise are catalyzing partnerships with external data providers and software vendors, while quality accreditation and scalability considerations drive laboratories to invest in automation, laboratory information management systems, and cloud-enabled pipelines. Taken together, these shifts mandate a strategic balancing act: adopting innovations that deliver clinical differentiation while ensuring compliance, cost control, and reproducibility in high-volume, regulated environments.

A rigorous analysis of how recent tariff adjustments reshape procurement resilience, operational continuity, and supplier strategies for clinical NGS laboratories

The implementation of new tariff measures in the United States in 2025 introduces immediate and cascading implications for CLIA-certified next generation sequencing laboratories that rely on global supply chains. Tariffs on imported reagents, consumables, and equipment components increase unit costs and complicate long-term procurement planning. Laboratories that previously optimized cost structures around predictable vendor pricing must now evaluate the sensitivity of their cost base to duty fluctuations and consider hedging strategies, multi-sourcing, or nearshoring to mitigate exposure.

Supply chain disruptions are another direct consequence, with extended lead times and allocation risks prompting laboratory managers to reassess inventory policies, safety stock levels, and supplier contracts. In certain instances, laboratories may face prioritization dilemmas when critical reagents or platform components become constrained, forcing a re-evaluation of test menus, throughput commitments, and clinical prioritization frameworks. These operational trade-offs have implications for turnaround time commitments and customer relationships, particularly for high-acuity services such as oncology panels and prenatal diagnostics.

The tariff environment also reshapes competitive positioning. Vendors with diversified manufacturing footprints or domestic production capabilities gain relative advantage, while smaller suppliers dependent on cross-border supply chains may experience margin compression or exit pressures. For laboratories, this means procurement strategies must increasingly incorporate supplier resilience metrics and total landed cost analyses rather than purely unit price comparisons. Additionally, the tariff context incentivizes collaborative approaches with sequencing platform manufacturers and reagent suppliers to secure long-term supply agreements, co-developed pricing models, or localized manufacturing arrangements that preserve service continuity and cost predictability.

Regulatory and compliance frameworks intersect with tariffs in nuanced ways. Changes to import regimes can affect lead times for validated components, necessitating revalidation efforts where alternates or substitute reagents are introduced. Laboratories must therefore build flexible validation pathways and ramp testing protocols that allow controlled substitution without compromising clinical integrity. In sum, the 2025 tariff adjustments force a strategic reorientation across procurement, operations, quality assurance, and commercial engagement to sustain service reliability and maintain margins under greater supply-chain volatility.

A granular exploration of service type, clinical application, end user, platform technology, and sample considerations that determine operational and interpretive complexity

Insightful segmentation illuminates where clinical value and operational complexity intersect across service type, application, end user, technology platform, and sample type. Service type distinctions among clinical exome sequencing, targeted gene panel testing, and whole genome sequencing reveal different validation burdens and clinical reporting demands; clinical exome efforts split between adult and pediatric exomes require specialized interpretive pipelines and distinct consent and variant curation practices, while targeted gene panels such as cancer, cardiovascular, and neurological disorder panels present scalable pathways for focused clinical utility. Within cancer panels, the distinction between hematologic panels and solid tumor panels creates divergent specimen processing requirements and bioinformatics workflows that laboratories must explicitly address.

Application-level segmentation underscores varied clinical evidence needs and specimen workflows. Infectious disease testing divides into bacterial and viral workflows with unique nucleic acid extraction and contamination control considerations, whereas inherited disease testing spans common conditions suitable for higher-throughput approaches and rare disease analyses that demand deep variant curation and multidisciplinary case review. Oncology applications bifurcate into hematologic malignancies and solid tumors, each with differing tissue handling demands and variant interpretation frameworks. Reproductive health applications, ranging from noninvasive prenatal testing to preimplantation genetic testing, impose stringent pre-analytic controls and counseling pathways that laboratories must operationalize.

End user segmentation differentiates service delivery models and commercial interfaces. Diagnostic laboratories, direct-to-consumer testing channels, hospitals and clinics, and research institutes each present unique requisition workflows, reporting expectations, and compliance obligations, requiring laboratories to calibrate client service models accordingly. Technology platform choices among BGI, Illumina, and Thermo Fisher sequencing platforms necessitate vendor-specific validation strategies and throughput planning; within these families, instrument variants such as Bgiseq 500, Mgiseq, MiSeq, NextSeq, NovaSeq, and Ion Torrent models introduce discrete technical and logistical considerations. Sample type segmentation across blood, saliva, and tissue embodies divergent pre-analytic and storage needs, where blood subsets like plasma versus whole blood and tissue formats such as FFPE versus fresh frozen demand tailored extraction and quality assessment procedures. Collectively, these layered segments define the operational playbook laboratories must design to ensure assay reliability, interpretive clarity, and fit-for-purpose clinical deployment.

A regional analysis of regulatory nuance, procurement dynamics, and adoption pathways shaping clinical genomic services across major global regions

Geographic dynamics continue to shape access to sequencing platforms, reagent supply chains, regulatory interpretations, and clinical adoption rates across the Americas, Europe Middle East & Africa, and Asia-Pacific, creating differentiated strategic priorities for laboratories operating in each region. In the Americas, integrated health systems and pockets of advanced oncology care drive demand for companion diagnostics and high-complexity sequencing services, while the regulatory environment emphasizes CLIA accreditation and payer engagement to achieve clinical acceptance and scaling.

Across Europe, the Middle East and Africa, heterogeneity in regulatory frameworks and reimbursement policies generates a patchwork market where laboratories must navigate divergent national requirements and data protection regimes. This environment favors flexible service models, partnerships with regional reference labs, and investments in localized clinical evidence to support adoption. In the Asia-Pacific region, rapid platform uptake, significant local manufacturing presence, and ambitious public health sequencing initiatives are catalyzing growth, but laboratories must manage complex logistics, multilingual reporting requirements, and variable reimbursement mechanisms to translate capability into sustainable clinical services.

The regional differences also influence talent availability, automation adoption, and laboratory consolidation trends. Markets with constrained skilled bioinformatics and clinical genetics capacity often rely more heavily on centralized reference labs or cloud-based interpretive services, whereas regions with concentrated specialist centers can support decentralized offerings and closer hospital-laboratory integration. Understanding regional regulatory nuances, procurement cycles, and clinical referral patterns enables laboratories to tailor go-to-market strategies that align with local demand signals and operational realities.

An in-depth look at vendor positioning, integrated solution strategies, and partnership models that determine competitive advantage in clinical sequencing services

Competitive dynamics among key companies are defined by technology portfolio breadth, global manufacturing and supply resilience, reagent and consumable ecosystems, and the depth of bioinformatics and clinical reporting support. Leading sequencing platform providers compete not only on read accuracy and throughput but also on downstream services such as assay kits, reference databases, and integrated informatics offerings that reduce the time and cost to clinical validation. Strategic partnerships between platform vendors and diagnostic laboratories accelerate assay adoption by aligning validation pathways and supply assurances, while companies investing in reagent reliability and localized production gain operational advantages under constrained supply conditions.

In parallel, companies that offer integrated solutions encompassing sample-to-report workflows, regulatory support, and clinician-facing interpretive tools are increasingly valued by laboratories seeking to shorten deployment timelines and minimize internal development overhead. The emergence of specialized players delivering curated variant databases, clinical decision support, and regulatory-ready documentation creates an ecosystem where laboratories can assemble best-of-breed components or adopt end-to-end solutions depending on strategic priorities. Competitive differentiation also arises from services tailored to high-value clinical applications such as oncology and reproductive health, where the ability to demonstrate clinical validity, report clarity, and actionable recommendations influences purchasing and referral decisions.

Finally, nimble vendors that provide flexible commercial models-subscription-based informatics, reagent-as-a-service, or collaborative validation programs-are well-positioned to support laboratories through technology transitions and regulatory change. As consolidation and strategic alliances continue, laboratories should evaluate partners based on technical performance, supply chain resilience, and the capacity to co-develop clinical workflows that align with institutional objectives.

Actionable strategic priorities for laboratory executives focused on procurement resilience, clinical differentiation, and scalable operational excellence

Industry leaders must pursue a dual strategy that balances near-term operational resilience with long-term clinical differentiation. First, prioritize supplier diversification and long-term contractual arrangements to protect against supply chain volatility and tariff impacts; this includes evaluating alternative vendors, localized manufacturing partnerships, and inventory strategies that preserve clinical continuity. Second, invest in modular automation and standardized quality systems that accelerate assay validation, reduce error rates, and support scalable throughput without sacrificing clinical interpretive rigor.

Third, strengthen bioinformatics and variant interpretation capabilities through a combination of internal talent development and external partnerships, ensuring reproducible pipelines, transparent curation policies, and clinician-friendly reporting. Fourth, deepen engagement with payers and clinicians to build evidence of clinical utility and pathway integration, focusing on high-impact applications such as oncology panels and reproductive health testing where diagnostic decisions directly inform care. Fifth, adopt flexible commercial models and customer support offerings that align with different end-user expectations-from hospitals requiring integrated EHR reporting to direct-to-consumer channels seeking simplified results and counseling frameworks.

Finally, embed regulatory foresight into strategic planning by cultivating capabilities for rapid revalidation, documentation management, and audit readiness. Leaders should also consider collaborative approaches with platform vendors and peer laboratories to share validation burden, harmonize reporting standards, and accelerate adoption of best practices. These combined actions will enable organizations to preserve service reliability, enhance clinical credibility, and capture opportunities created by evolving care pathways and technology advances.

A transparent methodology combining primary stakeholder interviews, technical validation review, and scenario stress-testing to inform operationally actionable insights

This research synthesizes primary engagements with laboratory leaders, platform vendors, clinical stakeholders, and subject-matter experts, combined with systematic review of regulatory guidance, peer-reviewed literature, and vendor technical documentation to produce a comprehensive and practical assessment. The methodology emphasizes triangulation: qualitative interviews contextualize operational realities, technical validations and protocol reviews illuminate assay performance constraints, and comparative analyses of platform specifications identify trade-offs relevant to clinical deployment.

Quality assurance in the research process included cross-validation of interpretive frameworks with practicing clinical geneticists and laboratory directors, and scenario stress-testing of procurement and supply-chain responses to tariff changes. The research also incorporated detailed mapping of sample workflows across specimen types-blood, saliva, and tissue-to identify pre-analytic vulnerabilities and mitigation strategies. Where possible, evidence was prioritized that reflects clinical workflows and regulatory compliance needs rather than marketing claims, ensuring that recommendations are implementable and aligned with accreditation requirements.

Analytical approaches focused on decomposing operational costs into process-level activities, evaluating validation timelines for different assay classes, and assessing vendor resilience across manufacturing footprints. Throughout, confidentiality and ethical considerations guided primary data collection, and methodologies were designed to be transparent and reproducible so that organizations can adapt the approach for their internal audits and strategic planning exercises.

A conclusive synthesis emphasizing strategic execution, supplier resilience, and clinical evidence pathways that enable sustainable growth in clinical genomics services

In conclusion, CLIA-certified next generation sequencing laboratory services are at an inflection point where technology advances, supply-chain dynamics, regulatory expectations, and shifting clinical adoption patterns converge to create both challenges and opportunities. Laboratories that proactively address procurement resilience, invest in robust bioinformatics and interpretive frameworks, and cultivate partnerships with platform vendors and clinical stakeholders will be best positioned to translate technological capability into reliable, clinically actionable services. The interplay between targeted panels, exome approaches, and whole genome testing requires a portfolio mindset that aligns assay choice with clinical utility, operational capacity, and regulatory obligations.

Furthermore, regional dynamics and tariff-related supply risks underscore the necessity for flexible validation pathways and diversified sourcing strategies. Companies and laboratories that prioritize quality systems, clinician engagement, and payer evidence-building can accelerate adoption while maintaining compliance and trust. Ultimately, success in this sector will hinge on disciplined execution across laboratory processes, strategic supplier relationships, and a relentless focus on delivering clear clinical value that integrates seamlessly into patient care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next Generation Sequencing CLIA Laboratory Services Market, by Service Type

  • 8.1. Clinical Exome Sequencing
    • 8.1.1. Adult Exome
    • 8.1.2. Pediatric Exome
  • 8.2. Targeted Gene Panel Testing
    • 8.2.1. Cancer Panels
      • 8.2.1.1. Hematologic Panels
      • 8.2.1.2. Solid Tumor Panels
    • 8.2.2. Cardiovascular Panels
    • 8.2.3. Neurological Disorder Panels
  • 8.3. Whole Genome Sequencing

9. Next Generation Sequencing CLIA Laboratory Services Market, by Application

  • 9.1. Infectious Disease
    • 9.1.1. Bacterial Infections
    • 9.1.2. Viral Infections
  • 9.2. Inherited Disease
    • 9.2.1. Common Disease
    • 9.2.2. Rare Disease
  • 9.3. Oncology
    • 9.3.1. Hematologic Malignancies
    • 9.3.2. Solid Tumor
  • 9.4. Pharmacogenomics
  • 9.5. Reproductive Health
    • 9.5.1. Noninvasive Prenatal Testing
    • 9.5.2. Preimplantation Genetic Testing

10. Next Generation Sequencing CLIA Laboratory Services Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Direct To Consumer Testing
  • 10.3. Hospitals And Clinics
  • 10.4. Research Institutes

11. Next Generation Sequencing CLIA Laboratory Services Market, by Technology Platform

  • 11.1. BGI Sequencing Platforms
    • 11.1.1. Bgiseq 500
    • 11.1.2. Mgiseq
  • 11.2. Illumina Sequencing Platforms
    • 11.2.1. MiSeq
    • 11.2.2. NextSeq
    • 11.2.3. NovaSeq
  • 11.3. Thermo Fisher Sequencing Platforms
    • 11.3.1. Ion Torrent Pgm
    • 11.3.2. Ion Torrent Proton

12. Next Generation Sequencing CLIA Laboratory Services Market, by Sample Type

  • 12.1. Blood
    • 12.1.1. Plasma
    • 12.1.2. Whole Blood
  • 12.2. Saliva
  • 12.3. Tissue
    • 12.3.1. Ffpe
    • 12.3.2. Fresh Frozen

13. Next Generation Sequencing CLIA Laboratory Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next Generation Sequencing CLIA Laboratory Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next Generation Sequencing CLIA Laboratory Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Next Generation Sequencing CLIA Laboratory Services Market

17. China Next Generation Sequencing CLIA Laboratory Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Adaptive Biotechnologies Corporation
  • 18.6. Agilent Technologies Inc
  • 18.7. ARUP Laboratories
  • 18.8. Azenta Life Sciences
  • 18.9. BGI Genomics Co Ltd
  • 18.10. Bio-Rad Laboratories Inc
  • 18.11. Charles River Laboratories Inc
  • 18.12. Eurofins Scientific SE
  • 18.13. F Hoffmann-La Roche AG
  • 18.14. Foundation Medicine Inc
  • 18.15. Fulgent Genetics Inc
  • 18.16. Guardant Health Inc
  • 18.17. Illumina Inc
  • 18.18. Invitae Corporation
  • 18.19. IQVIA Laboratories
  • 18.20. Macrogen Inc
  • 18.21. Myriad Genetics Inc
  • 18.22. Natera Inc
  • 18.23. NeoGenomics Laboratories
  • 18.24. Novogene Corporation
  • 18.25. Oxford Nanopore Technologies plc
  • 18.26. Personalis Inc
  • 18.27. QIAGEN N V
  • 18.28. Quest Diagnostics Incorporated
  • 18.29. Thermo Fisher Scientific Inc
  • 18.30. Veracyte Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PGM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PGM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PGM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PROTON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PROTON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PROTON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FFPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FFPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FFPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FRESH FROZEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FRESH FROZEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FRESH FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE NEXT GENERATION SEQUENCIN